NASDAQ:EVGN - Nasdaq - IL0011050551 - Common Stock - Currency: USD
Taking everything into account, EVGN scores 2 out of 10 in our fundamental rating. EVGN was compared to 561 industry peers in the Biotechnology industry. EVGN may be in some trouble as it scores bad on both profitability and health. EVGN is valued quite expensive, but it does show an excellent growth.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -41.35% | ||
ROE | N/A | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 68.48% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | N/A | ||
Debt/FCF | N/A | ||
Altman-Z | -11.01 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.15 | ||
Quick Ratio | 1.06 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NASDAQ:EVGN (5/23/2025, 11:40:42 AM)
1.18
-0.01 (-0.84%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 0.9 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | N/A | ||
P/tB | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -41.35% | ||
ROE | N/A | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 68.48% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | N/A | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 25% | ||
Cap/Sales | 7.36% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 1.15 | ||
Quick Ratio | 1.06 | ||
Altman-Z | -11.01 |